

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number
WO 2005/033082 A3

(51) International Patent Classification⁷: C07D 215/42 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/IB2004/003054

(22) International Filing Date: 20 September 2004 (20.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/507,385 30 September 2003 (30.09.2003) US

(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DALVIE, Deepak, Kamalnath [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). RUGGERI, Roger, Benjamin [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agent: FULLER, Grover, F., Jr., c/o Lawrence, Jackie, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT 06340 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report: 16 June 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CETP INHIBITORS AND METABOLITES THEREOF

(57) Abstract: Compounds resulting from the administration of torcetrapib to a mammal, and the use of such compounds as an indicator or biomarker to the presence or exposure of torcetrapib in the plasma of a mammal including humans. The invention is also directed to cholestryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)-cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycerides.

WO 2005/033082 A3